PRM13 Strengthening Evidence Base for Traditional Medicine in Asean, Quality of Reporting of Randomised Controlled Trials of Herbal Interventions in Asean Plus Six Countries: A Systematic Review  by Pratoomsoot, C. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A545
Objectives: Traditional Medicine and the use of herbal interventions are regarded 
as an integral part of health care among countries of Association of Southeast Asian 
Nations (ASEAN). To date numerous randomised controlled trials (RCTs) of herbal 
interventions have been conducted within ASEAN. It is recognised that good qual-
ity reporting of RCTs is crucial to the assessment of clinical significance. ASEAN 
has placed strong emphasis on the facilitation of research in Traditional Medicine, 
especially in the strengthening of evidence base for herbal medicines. The objective 
of this study was to systematically review the quality of reporting of RCTs of herbal 
interventions conducted in ASEAN Plus Six Countries. MethOds: Searches were 
performed using PubMed, EMBASE and MEDLINE, The Cochrane Library, and Allied 
and Complementary Medicine (AMED), from inception through October 2013. The 
following limits were applied: Human; RCTs. Herbal species search terms were 
based on those listed in the National List of Essential Medicines [NLEM (Thailand, 
2011)]. Studies conducted in ASEAN Plus Six Countries, published in English were 
included. Quality of reporting was assessed according to the 22-item Elaborated 
CONSORT statement for reporting RCTs of herbal interventions. Results: Seventy-
one articles were identified, of which thirty RCTs (42.25%) were conducted in ASEAN 
Countries, whereas 41 RCTs (57.75%) were from the Plus Six Group. Adherence to 
the recommended CONSORT checklist items for reporting of RCTs of herbal inter-
ventions among ASEAN Plus Six Countries ranged from 0% to 97.18%. Less than 
half of the RCTs reported methods used to generate random sequence allocation 
(item 8,47.89%), and implement random allocation sequence (item 9 allocation con-
cealment, 29.58%). Less than a quarter of RCTs (18.31%) reported information on 
standardisation of herbal products. cOnclusiOns: The present study highlighted 
the need to improve reporting quality of RCTs of herbal interventions across ASEAN 
Plus Six Communities.
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Objectives: A wide range of instruments are used to measure outcomes in clinical 
studies of chronic pain. However, the suitability of study outcomes for economic 
evaluations in chronic pain is limited by variability in the instruments used and 
the failure of those that are in common use to adequately capture the dimensions 
of a patient’s experience of pain, including function, quality of life and tolerability. 
The current study aims to identify the pain instruments and study endpoints most 
commonly used in the clinical trial setting. MethOds: A structured, comprehensive 
literature review of ongoing registered trials (trial registries) and published clini-
cal studies (PubMed) in the areas of chronic pain (cancer, non-cancer and neuro-
pathic), pain in elderly patients, and breakthrough pain was conducted. Inclusion 
criteria were: interventional study, pain population of interest and pain measured 
within primary endpoint. Data were extracted from identified publications focus-
ing on primary and secondary endpoints reported, and primary pain instrument 
used. Results: Of 1,256 citations retrieved, 132 were included as they reported 
large clinical studies in pain populations. The majority of primary endpoints were 
pure pain measures (112), most commonly: numerical rating scale (NRS) (44), visual 
analogue scale (VAS) (34), and brief pain inventory (BPI) (18). Other outcome domains 
were typically limited to secondary endpoints and were not consistently applied 
across the studies. These include measures of function (47), quality of life (36), 
safety/tolerability (33), emotional wellbeing (26) and sleep (20). cOnclusiOns: 
The majority of studies still use simple pain measures as their primary outcomes. 
Useful economic outcomes such as quality of life and function are relegated to 
secondary endpoints and are inconsistently used. Types of pain instruments cur-
rently used in registered, ongoing trials will also be reported. Further research is 
needed to consider which existing endpoint designs constitute best practise and 
if new designs are required.
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Objectives: Comparing outcomes between different treatments based on real 
world evidence can be challenging, first because of confounding due to lack of ran-
domization at treatment initiation, and secondly due to selection bias induced by 
selective treatment switching. To account for both sources of bias, we explored the 
Inverse probability of censoring weights analysis (IPCW) to account for this bias on 
a retrospective dataset of multiple myeloma patients in Sweden. MethOds: IPCW-
approach was used to additionally adjust for bias induced by selective treatment 
switching in 2 steps. First, time-varying weights were estimated using multivariate 
logistic regression, including age, gender, stage, M-protein type, creatinine-clearance 
as baseline covariates and M-protein as time-varying covariate. Secondly, these 
time-dependent weights were incorporated in a proportional hazards model, includ-
ing treatment and baseline characteristics, with patients censored at initiation of 
subsequent therapy. ITT-estimates were generated based on multivariate propor-
tional hazards model, including the same baseline covariates. Results: In the total 
MM population (n= 1638), the non-transplant population was 1125, of which 31% 
(n= 349) received novel therapies (bortezomib, lenalidomide and thalidomide based) 
while 69% had conventional therapies in frontline. Mean age was 71/75 respectively. 
The mean baseline serum m-protein level was 30.9 g/L for both groups. The ITT HR in 
frontline was 0.56 [0.45, 0.70] and IPCW-adjusted HR is 0.31 [0.22, 0.42]. ITT vs IPCW-
based HR for 2nd and 3rd line of therapy were 0.71 [0.58, 0.87] vs 0.667 [0.487, 0.914] 
75% improvement from baseline in PASI (PASI 75) at the end of the trial were identi-
fied from two recently published NMAs focused on the efficacy of biologics in the 
treatment of moderate to severe psoriasis based on a systematic literature review. 
Differences in baseline risk of PASI 75 were explored graphically. The association 
between the treatment effect of 19 different biologics and baseline risk of PASI 
75 with placebo was assessed by conducting a Bayesian NMA with baseline risk 
covariate adjustment using a model assuming a constant treatment by covariate 
interaction, and a normal distribution for baseline risk. The model also allowed for 
the baseline risk adjustment of RCTs that did not include a placebo arm. Results: 
Across the RCTs, PASI 75 at the end of the trial period for patients in the placebo arm 
ranged from 2% to 19%. The coefficient for baseline risk was a median of -0.33 (95% 
credible intervals: -0.79, 0.21) which suggested baseline risk was not significantly 
associated with the proportion achieving PASI 75 across the RCTs. cOnclusiOns: 
Based on a NMA of RCTs regarding the efficacy of biologics in terms of PASI 75, it 
is unclear if baseline risk of PASI 75 acts as a treatment effect modifier. Further 
analyses are required to assess whether baseline risk may explain differences in 
the classes of biological therapies used to treatment moderate to severe psoriasis.
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Objectives: Submissions to Health Technology Assessment (HTA) bodies must 
include the most up-to-date information on comparator technologies. This ena-
bles HTA bodies to make fully informed decisions. In order to ensure up-to-date 
information is obtained, all relevant data sources should be searched. At present 
HTA method guidelines generally specify that a core set of databases comprising 
EMBASE, MEDLINE, MEDLINE-in-process and the Cochrane Library are searched. 
However, in an attempt to manage the increasing quantity of research, journals 
are publishing more articles ahead of print as online e-publications. E-publications 
ahead of print are identifiable in PubMed but are not indexed in EMBASE, MEDLINE 
or Cochrane. MethOds: We selected a NICE guideline published in June 2014 for 
ablation techniques in atrial fibrillation which searched for randomised clini-
cal trials (RCT) in the common databases. We updated the searches in EMBASE, 
MEDLINE, MEDLINE-in-process and the Cochrane Library from the date of the last 
search, to identify any studies published since the guideline was published. We 
concurrently searched PubMed using a filter to identify studies only available as 
e-publications ahead of print. Results: We identified one RCT meeting the inclu-
sion criteria that was retrieved by the search in PubMed but was not identified by 
searching in EMBASE, MEDLINE or Cochrane (all searches being run on the same 
date). cOnclusiOns: If studies are missed from systematic reviews there can be 
important implications on clinical efficacy comparisons. To produce the most up-
to-date systematic review, with all available full papers it is necessary to search 
for e-publications ahead of print in PubMed as well as for all other publications in 
EMBASE, MEDLINE and Cochrane.
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Objectives: To produce a modern, accessible, quick and intuitive growth prediction 
tool in which growth prediction models (GPMs) were clinically validated. MethOds: 
GPMs support physicians to optimise and monitor GH treatment and response. They 
are validated, providing accurate predictions of growth response following GH treat-
ment in children with idiopathic growth hormone deficiency (IGHD), Turner syn-
drome (TS) and short children born small for gestational age (SGA). By using GPMs, 
realistic expectations of treatment outcomes are conveyed to patients and parents 
(important as children respond differently to treatment). A modern platform, a 
website, will host iGRO; the software should ensure web browser compatibility in 
European endocrine clinics. An internal paediatric endocrinologist robustly tested 
the GPMs. User acceptance testing (UAT) for acceptability and usability was con-
ducted with external paediatric endocrinologists. These outputs contribute to the 
Class I medical device Technical File; a requirement for iGRO. Results: The clinical 
validation performed under simulated conditions using the final medical device 
software passed, consistent with regulatory expectations. GPMs for IGHD, SGA, TS 
were tested for prediction accuracy. Validation acceptance criteria and test results 
were included in the test script records. UAT was designed and executed following 
a rigorous software development lifecycle methodology to ensure completeness 
of the tool and the specified business and user requirements. UAT was certified 
through role based testing scenarios (requirements and processes for daily use). The 
tool, accessed via a secure password protected website, was easily navigated and 
provided a clear interface requiring little training. Data entry was quick and growth 
outcomes (i.e. graphical comparisons between patient’s actual growth response and 
one-year predictions) were easily viewed. cOnclusiOns: iGRO, an accessible web-
based software medical device, provides accurate growth prediction which enable 
physicians to monitor patients’ response to GH treatment. It may potentially be 
used to detect discrepancies early.
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